Moreover, in a preclinical mouse model of non-Hodgkin lymphoma using anti-CD20 target therapy, the expression of galectin-1 ablated antibody-dependent lymphoma phagocytosis in vitro and lymphoma cell sensitivity to CD20 immunotherapy in vivo. This evidence concerns the gene LGALS1 and lymphoma.